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Abstract  
NASH/NAFLD is rapidly becoming one of top causes of cirrhosis, hepatocellular carcinoma and 
indication for liver transplantation. Except for life style modification through diet and exercise, 
there are currently no other approved treatments for NASH/NAFLD. Although weight loss can 
be effective, it is hard to achieve and sustain. In contrast, bariatric surgery can improve metabolic 
conditions associated with NAFLD and has been shown to improve liver histology. In order to 
have approved regimens for treatment of NASH/NAFLD, a number of issues that must be 
addressed.  First, all stakeholders must agree on the most appropriate clinical trial endpoints for 
NASH. Currently, resolution of NASH (without worsening fibrosis) or reduction of fibrosis stage 
(without worsening NASH) are the accepted endpoints by the regulatory authorities.  It is 
important to recognize the prognostic implication of histologic features of NASH. In this 
context, although histologic NASH has been associated with advanced stage of fibrosis, it is not 
an independent predictor of long term mortality. In contrast, there is significant data to suggest 
that stage of fibrosis is the only robust and independent predictor of liver-related mortality. In 
addition to the primary endpoints, a number of important secondary endpoints, including non-
invasive biomarkers, long term outcomes, and patient reported outcomes, must be considered. In 
2017, a few phase 3 clinical trials for treatment of NASH are in progress. Additionally, a number 
of phase 2a and 2b clinical trials targeting different pathogenic pathways in NASH enriches the 
pipeline of emerging therapies. Conclusion: Over the next 5 years, some of these regimens are 
expected to provide potential new treatment options for patients with NASH/NAFLD. 
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Background:  
NAFLD is rapidly being recognized as the leading cause of chronic liver disease worldwide. [1-
3] Over the past two decades, there is substantial evidence to suggest that NAFLD is highly 
prevalent throughout the world and represents a spectrum of diseases, some of which can 
progress to cirrhosis and hepatocellular carcinoma (HCC). [2-5] The majority of subjects with 
NAFLD are asymptomatic and are diagnosed incidentally. Although all subtypes of NAFLD 
increase the risk for the cardiovascular events and mortality, NASH is the main diagnostic 
subtype of NAFLD which predisposes patients to cirrhosis and liver-related complications [1-3]. 
 In 2017, there are no approved drug treatments for NAFLD and NASH. [6] Nevertheless, a large 
number of emerging therapies are being evaluated in clinical trials. As our understanding of the 
basic pathogenesis of the progressive form of NAFLD increases, almost certainly, there will be 
new treatment targets considered and new treatment regimens to be developed for NASH 
patients at risk of progressive hepatic fibrosis and its associated clinical outcomes. [1-8] 
In the quest to find an effective and safe treatment for the progressive form of NAFLD, a number 
of priorities and challenges must be recognized. First, as noted previously, NASH represents the 
potentially progressive form of NAFLD and as such, it should be the target of treatment. 
Furthermore, the severity of hepatic fibrosis (i.e. fibrosis stage) predicts liver-related mortality in 
NAFLD and therefore, patients with significant hepatic fibrosis must be the cohort for whom 
development of treatment regimens is prioritized. [7-10] In addition to the appropriate endpoints, 
it is important to consider the placebo effect on the histology of NASH patients treated in 
randomized controlled trials. In fact, this placebo effect has been shown to be substantial. [11] 
Additionally, spontaneous regression of NASH and even NASH-related fibrosis has been 
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observed, potentially related to the life style modifications and behavioral changes of these 
subjects during the clinical trial. [11] An example of this phenomenon was observed in the 
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsored 
Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with 
Nonalcoholic Steatohepatitis (PIVENS) trial, where placebo-treated subjects experienced 
significant weight loss. [11] In fact, the interaction with weight loss during a clinical trial can be 
an important confounder when evaluating the histologic response of patients with NASH. [12] 
In this context, an important challenge in the field of NASH therapeutics is to develop a 
consensus on how to accurately assess treatment response. There is ongoing debate as to what 
endpoint truly represents the best surrogate for the “hard” outcomes (liver-related morbidity and 
mortality) in NAFLD/NASH. Although still debated, improvement of stage of fibrosis, may 
represent the best endpoint that can be used in the clinical trials of NASH. Although resolution 
of histologic NASH does correlate with the improvement of fibrosis, it may be flawed by the 
variability inherent in its histologic assessment. In addition to the clinical endpoints, inclusion of 
validated patient reported outcomes in therapeutic trials of NASH will be important. [9,13] 
 
This manuscript is the summary of the current and future treatment modalities that were 
presented in a recent Trend conference on NASH sponsored by the American Association for the 
Study of Liver Disease (AASLD).  
Selection of End Points in the Clinical Trials of NASH 
Until recently, therapeutic trials of NASH have primarily focused on improvement in 
steatohepatitis as defined by the NAFLD Activity Score (NAS). [14] In addition to the 
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improvement of NAS score, resolution of histologic evidence for NASH is also considered an 
important primary endpoint in most clinical trials for patients with NASH. [15] In this context, it 
is important to recognize that although NAS scoring does provide valuable quantifiable scores to 
assess the individual histologic components of NASH, the grading is still subjective. [16]   The 
inter-observer variability of histologic components of NAS such as ballooning degeneration (a 
key pathologic feature of NASH) has been problematic. [14, 17] Additionally, ballooning 
degeneration as an individual pathologic feature is not an independent predictor of liver-related 
mortality. [14, 17] In this context, the endpoint should be a surrogate of the hard outcome of 
liver-related mortality. As noted previously, there is now increasing evidence that stage of 
fibrosis is the best predictor of mortality and may serve as the best surrogate for clinically 
relevant outcomes in NASH. [8, 18]   
In addition to histology, other important endpoints in NASH subjects with cirrhosis include 
measurement of hepatic venous pressure gradient (HVPG). The selection of this endpoint is 
based on the data suggesting that HVPG values above a certain threshold is associated with 
reduced survival in patients with cirrhosis [19] Although improvement in survival is always 
desirable, given the long natural history of NASH and presence of comorbidities in this 
population, studies designed to capture this endpoint will be difficult to design and will not be 
feasible to carry out.  
Although there is little doubt about the value of histologic assessments in NASH, liver biopsy is 
invasive and not easily accepted by patients. Furthermore, repeat biopsies to assess worsening or 
improvement of liver injury and histologic fibrosis in clinical practice is not feasible. Therefore, 
a flurry of efforts to develop and validate non-invasive modalities to assess the stage of fibrosis 
in NASH and to document its progression and regression has ensued. Challenges surrounding the 
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ability to non-invasively define these therapeutic endpoints must be overcome to truly advance 
the therapeutic field of NAFLD and NASH. 
Finally, it is important not only to include important clinical endpoints that best predict mortality 
but also to include patient-reported outcomes that are the best surrogates of patient experience. In 
this context, the use of disease specific validated instrument such as the chronic liver disease 
questionnaire (CLDQ)-NAFLD-NASH in the clinical trials of NASH will be important. [13] 
Data Regarding Weight Loss and Exercise in NAFLD  
Life style modification including weight loss and structured exercise remains the cornerstone of 
treatment for patients with NAFLD and NASH. [20] In this context, weight loss has been 
associated with a reduction in liver fat and improvement in aminotransferases. [6] The amount of 
weight lost is a determinant of histologic improvements in liver injury and fibrosis. Though 
small reductions (3–5% body weight loss) can reduce hepatic steatosis and the associated 
metabolic parameters, the larger weight reduction (at least 7%) is required to observe 
improvement or resolution of steatohepatitis. [21-22]  
 
In the context of mild to moderate obesity, weight loss can be achieved by dietary interventions 
that restrict calorie intake. [21] However, it should be noted that long-term sustained weight loss 
can only be experienced by 3-6% of subjects. [6, 21] Although the benefit of different diets may 
vary according to the underlying metabolic abnormalities, the Mediterranean diet has been 
demonstrated to have a beneficial role in reducing all-cause mortality, cardiovascular diseases, 
cancer, obesity and type 2 diabetes. [22] However, the efficacy of these different diets in 
patients with NASH has not been formally assessed. Nevertheless, dietary macronutrient 
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composition generally seems to have a lesser role than caloric restriction to reduce liver fat in 
patients with NAFLD. [21,22]  
 
In addition to diet, physical activity plays an important role in the development of NAFLD. 
[23,26] In this context, about half of NAFLD patients are inactive, and a third of these patients 
do not perform any physical exercise. [23] Based on the recent data, there has been increasing 
recognition of the efficacy of exercise per se in reducing hepatic fat. Therefore, exercise is now 
routinely recommended for the management of NAFLD. [27, 28] In addition to improvement in 
hepatic steatosis, exercise has also been shown to improve liver enzymes and ameliorate insulin 
resistance. [24] In this context, it can be anticipated that exercise may improve liver 
inflammation and liver cell injury in patients with NAFLD. In fact, a recent study of 169,347 
men and women with repeat measures of liver fat (quantified with ultrasound) and physical 
activity, demonstrated a strong association between exercise and changes in NAFLD over a 
mean five years of follow up. [29] 
 
Although exercise is generally beneficial, the optimal dose of exercise may have relevance for 
subjects with NAFLD and NASH. Several recent studies have attempted to address the issues of 
optimal exercise dose (type, intensity and amount) for subjects with NAFLD. Some reports 
have suggested that there are no differences in the amount of liver fat reduction by aerobic 
exercise dose or intensity. In this context, only the act of exercising seems to be important. [24-
29] Additionally, another study has suggested that the reduction of liver fat by aerobic exercise 
occurred without a clinically significant weight loss, suggesting that exercise alone is an 
independent factor of reducing liver fat. [25] In this context, the current recommendations 
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suggest that resistance training should complement, aerobic exercise. In fact, this 
recommendation is also consistent with the exercise guidance for cardiovascular disease risk 
modification. [25,26] 
 
In summary, diet and exercise should remain the first line of therapy for NASH. However, more 
clinical research is needed to better understand the magnitude of improvement in clinical and 
histologic outcomes and determine the interaction between weight loss and exercise in subjects 
with NASH/NAFLD. 
 
The Current Medical Treatment for Patients with NASH  
The American Association for the Study of Liver Disease (AASLD) guidelines recommend that 
only biopsy-proven NASH should be considered for medical treatment. [27,28] There have been 
several drugs tested for the treatment of NAFLD but are not yet recommended due to discordant 
results and/or lack of therapeutic benefit in randomized controlled trials.  [30-37] 
In this context, glitazones are a class of drugs that have been used to treat NASH. Glitazones 
upregulate adiponectin, an adipokine with anti-steatogenic and insulin-sensitizing properties, 
which increase the synthesis and uptake of the fatty acids by the adipocytes, rather than being 
taken-up by organs, such as the liver and muscle. [33,34] One such drug, pioglitazone has been 
shown to improve histological NASH in terms of steatosis, inflammation, hepatocyte ballooning, 
NAS score and resolution of NASH as well as improving fibrosis as noted in a recent meta- 
analysis. [37,38] However, the beneficial effects are not sustained when the drugs are 
discontinued as alanine aminotransferase (ALT) values return to baseline and NASH reappears. 
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Additional concern is also related to the weight gain that accompanies the use of pioglitazone. 
[37]  
The most recent version of AASLD Guidance document for NAFLD suggests that since it 
appears that pioglitazone improves liver histology for patients with and without type 2 diabetes 
mellitus, it may be a viable option for treatment but only after review of the risks and benefits for 
patients.  In addition, prior to starting treatment of a diabetic patient, a liver biopsy should be 
considered to document histologically-proven NASH. [28]  
 
Vitamin E is an antioxidant which prevents liver injury by blocking intrinsic apoptotic pathways 
and by protecting against oxidative stress. [33] Data from the PIVENS trial showed that vitamin 
E can improve histological NASH in terms of steatosis, inflammation, ballooning, NAS score, 
and resolution of NASH at a dose of 800 IU/day. [11] However, there are some concerns that 
long term use of vitamin E may be associated with increased incidence of hemorrhagic stroke 
and an increased risk of prostate cancer. [33] Nevertheless, AASLD Guidelines suggest that 
Vitamin E may be used daily at a dose of 800 IU/day in nondiabetic adults with biopsy-proven 
NASH. However, at this time AASLD does not recommend the use of Vitamin E as treatment 
for NASH in diabetic patients, NAFLD without liver biopsy, NASH cirrhosis, or cryptogenic 
cirrhosis. [28] It important to note that the beneficial impact of vitamin E or pioglitazome on all-
cause mortality and liver-related mortality, has not been established.  
 
Liraglutide, a long acting GLP-1 (glucagon-like peptid-1) agonist, is secreted after eating. GLP-1 
is secreted by the L cells of the small bowel and proximal colon which stimulates insulin 
secretion by the pancreatic beta cells, decreases hepatic glucose production, increases satiety by 
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delaying gastric emptying, and has cardioprotective effects. [12] GLP-1 has a half-life of less 
than 2 minutes, while, liraglutide, the synthetic analogue, has a half-life that allows a single daily 
administration. [39] In a phase II trial, liraglutide 1.8 mg subcutaneous injection administered 
once daily, resulted in resolution of NASH while improving key metabolic risk factors [weight, 
body mass index (BMI), glucose level, and high density lipids (HDL) cholesterol] with minimum 
of side effects (mainly gastro-intestinal, such as diarrhea). [12] Phase III trials are awaited to 
confirm these preliminary data. 
 
It is important to remember that a large proportion of patients with NAFLD require treatment of 
their metabolic risk factors. In fact, preliminary data suggest that there may be an added benefit 
to the liver when the associated co-morbidities are treated.  [37-41] For instance, statins are safe 
to use in NAFLD population and can provide the beneficial effect of treating dyslipidemia, 
improving insulin resistance and reducing the risk of HCC. [40,41,42] Additionally, Ezetimibe 
and rosuvastatin also appear to be safe and potentially beneficial in patients with NAFLD [39,43] 
 
In summary, despite the initial assessment of a large number of agents, no single agent or 
combination has proven efficacy for subjects with NASH. Until the results of the ongoing 
randomized, double-blind, placebo-controlled trials become available, lifestyle modifications and 
optimizing metabolic risk factors are the best medical treatment option for patients with NASH.  
 
The Current Surgical Options for Treatment of Obesity in Subjects with NASH  
As noted previously, sustained weight loss can be beneficial for NAFLD. In this context, 
bariatric surgery can induce long-term weight loss and decrease long-term mortality related to 
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diabetes, heart disease, and cancer. [44,45] In a study with more than 10 years of follow-up, 
weight loss of 25%, 16%, and 14 % were noted in patients who underwent gastric by-pass, 
vertical banded gastroplasty, and gastric banding; respectively. [45] In addition, bariatric surgery 
can prevent cardiovascular events [46] and improve type 2 diabetes [47,48]   
 
It is important to note that, regardless of the type of bariatric surgical procedure performed, a 
decrease in adiposity is seen after bariatric surgery. This is an important factor to take into 
account as increased adiposity is associated with increased insulin resistance which is 
independently associated with hepatic steatosis.  In fact, persistence of insulin resistance is an 
independent predictor of presence of NAFLD one year after surgery and significantly increase 
the probability of having severe steatosis compared to those patients whose insulin resistance 
improved after their surgery. [49,50]  
 
Preliminary studies have also reported a resolution of NASH in approximately 85%–90% of 
patients who undergo gastric banding or bypass surgeries. [51] A recent prospective study 
analyzing sequential liver biopsies from a final cohort of eighty two patients with biopsy-proven 
NASH showed the disappearance of NASH in approximately 85% of the patients one year later- 
though NASH resolved in a greater proportion of patients with baseline mild disease (94%) than 
from those with baseline moderate or severe disease (70%). [52] Specifically, bariatric surgery 
significantly reduced all the histological components of NASH including hepatic fibrosis. [52] 
 
Despite these data, NASH is currently not an indication for bariatric surgery. In fact, patients 
with NASH must have other qualifying conditions as delineated by the national institute of 
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health consensus conference to be able to undergo weight loss surgery. [53] It is possible that 
this recommendation be changed since weight reduction surgery appears to effectively address 
metabolic conditions can lead to a reversal of NASH. 
 
Liver Transplantation in Subjects with NASH  
Liver transplantation (LT) is the standard treatment option for NASH and advanced liver disease. 
Currently, cirrhosis due to NASH is now the second most common indication for liver 
transplantation in the United States, with patients transplanted for NASH having similar survival 
as those transplanted for other etiologies. [54-57] In fact, the 1 year, 3 year, and 5 year survival 
rates post LT for patients with NASH are: 87.6%, 82.2%, and 5-year 76.7%, respectively, rates 
comparable to other indications. [57]   However, NASH after LT can either recur or can develop 
de novo in transplanted patients. [58]  While the risk of steatosis is time dependent and 
approaches 100% at 5-years after LT in NASH patients, the risk of developing histologic NASH 
is ~10-30%, while the risk of developing advanced fibrosis is low (5% at 5 years and 10% at 10 
years). [2, 5, 7]   In multivariate analysis, post-LT recurrence of NAFLD has been found to be 
associated with hypertriglyceridemia, and high BMI post-LT. [59] 
 
Post-transplant care for LT recipients with NASH can present several challenges. There is a 
strong rationale for adopting a minimalist approach to maintenance of immunosuppression for 
patients with a history of NASH. Lowest necessary doses of calcineurin inhibitors, mammalian 
target of rapamycin inhibitors and antimetabolites are recommended. Corticosteroids can cause 
and exacerbate features of the metabolic syndrome and should be avoided beyond the early (first 
6 months) postoperative period. [57,60] 
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In addition, there are no definitive data regarding the optimal time to biopsy recipients who were 
transplanted for NASH or cryptogenic cirrhosis. A significant portion of patients with NASH can 
have normal liver enzymes. The emergence and availability of transient elastography (TE) and 
magnetic resonance elastography may reduce the need for liver biopsy. [61] Weight gain is 
nearly ubiquitous following liver transplantation. Since obesity and the components of the 
metabolic syndrome are important predictors of posttransplant outcomes, management of weight, 
is a cornerstone of optimizing outcomes, and a deterrent to posttransplant metabolic syndrome, 
[62,63]  
 
In summary, NASH patients who undergo liver transplantation do very well. Nevertheless, these 
patients do present pre-transplant and post-transplant challenges. Optimal approaches to pre- and 
perioperative management (including bariatric surgery), immunosuppression, nutritional, 
psychological and pharmacotherapeutic agents are evolving rapidly but have not been fully 
accepted.  
 
Emerging Therapy for NASH: Non-Antifibrotic and Antifibrotic Regimens 
As the pathogenesis of NAFLD/NASH continues to unfold, multiple pathogenic pathways 
(insulin resistance, lipotoxicity, oxidative stress, altered immune/cytokine/mitochondrial 
functioning, and apoptosis) are being implicated in the development of NASH and its 
progression. [64] Therefore, new therapeutic modalities are being developed to target many of 
these pathways. These treatment regimens are currently in various stages of development with 
most of the current studies conducted with a single treatment modality (Table 1). However, it is 
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expected that combination therapy of multiple drugs to treat NASH will soon follow. The 
following will highlight the current treatment regimens in clinical trials directed towards 
improving hepatic steatosis, inflammation, liver cell injury, and fibrosis.  
 
One of the drugs that has progressed to phase 3 development for NASH is obeticholic acid 
(OCA) which is a farnesoid X receptor (FXR) agonist whose potential actions include a decrease 
of hepatic steatosis, inflammation, and fibrosis and dyslipidemia while increasing insulin 
sensitivity.  In the Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment (FLINT) 
phase 2 trial where OCA was compared to a placebo, investigators found no worsening of 
fibrosis as well as a decrease in the NAS score of ≥ 2 points for those on OCA. Although there 
was some evidence of worsening dyslipidemia, co-administration of statins led to the 
improvement of the participant’s low density profile (LDL) lipid profile to at or below baseline 
levels. [65]  
A phase 3 clinical trial of OCA in non-cirrhotic patients with NASH (stage 2 and 3) is ongoing 
[Randomized Global Phase 3 Study to Evaluate the Impact on NASH with Fibrosis of 
Obeticholic Acid Treatment (REGENERATE- 
https://clinicaltrials.gov/ct2/show/NCT02548351)]. The primary endpoint of the study is either 
improvement of fibrosis without worsening NASH or resolution of NASH without worsening 
fibrosis. A number of secondary endpoints and long term outcomes are being monitored for 
assessment of both efficacy and safety.  
 
Another agent in phase 3 clinical trial is elafibranor, a dual receptor peroxisome proliferator 
activated alpha/delta (PPAR α/ δ) agonist. Elafibranor was studied in the GOLDEN Study 2b 
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trial, and its effects were compared to a placebo. [35] Despite some methodological limitations 
of the GOLDEN trial, elafibranor, 120 mg/d for a year, induced resolution of NASH without 
fibrosis worsening in the ITT population. The effect seemed to be stronger in patients with more 
advanced NASH activity. Elafibranor was also well tolerated and improved patients’ 
cardiometabolic risk profile. However, patients did experience an increase in their creatinine 
level that resolved when the medication was stopped. [35] The ongoing phase 3 clinical trial of 
elafibranor (RESOLVE-IT) has identified the primary end point for the study as resolution of 
NASH without worsening of fibrosis. The study is also following long-term outcomes such as 
all-cause mortality, cirrhosis, and liver-related clinical outcomes. 
 
A phase 2 clinical trial assessed the safety and efficacy of Selonsertib with or without 
Simtuzumab in subjects with NASH stage 2 or 3 fibrosis. [66] The primary endpoint of the study 
was improvement of fibrosis without worsening of NASH. A number of other secondary 
endpoints were assessed. The study suggested significant histologic improvement as well as 
improvements in a number of secondary endpoints. [66] However, based on the recent data 
documenting the lack of efficacy of Simtuzumab, Simtuzumab was considered to have a placebo 
effect. Based on these data, a phase 3 clinical trial is being initiated and enrolling subjects with 
NASH and advanced fibrosis (STELLAR-3 and -4). The trial consists of a 48-week trial of 
Selonsertib in subjects with NASH stage 3 and 4. The primary endpoint is a ≥ 1 point decrease in 
fibrosis stage without worsening of NASH ballooning or inflammation. The study’s five-year 
outcome is the reduction in progression to cirrhosis (STELLAR-3) and hepatic decompensation, 
HCC, transplant, or death (STELLAR-3 and -4). [67] 
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Another phase 2 clinical trial is investigating the improvement in insulin sensitivity and NAFLD 
using the GLP-1 analogue, liragtytide semaglutide. [68] Additionally, another trial for treatment 
of NASH focuses on an acyl co-A carboxylase (ACC) inhibitor, which is a rate limiting step in 
the de novo lipogenesis. In a very small open label study, an ACC inhibitor showed reduction in 
ALT, elastometry and MRI PDFF quantification of liver fat [69] 
Despite the great enthusiasm and activity in the field of NASH therapeutics, there is no currently 
FDA approved treatment for NASH. Nevertheless, it is almost certain that our armamentarium of 
therapeutic options for NASH is likely to expand in the near future.  
There are also drugs in development designed to disrupt fibrosis development in patients with 
NASH. This is an area of significant therapeutic need since fibrosis is the strongest predictor of 
mortality in patients with NASH. [18,70,71]  
Currently, all ongoing Phase 2B or Phase 3 clinical trials of anti-fibrotic drugs require liver 
biopsy to quantify fibrosis before and after treatment. As noted previously, this requirement 
imposes limitations on the clinical trial design including the invasive nature of biopsy, which 
limits access to tissues at intermediate time points during the trial. Moreover, while biopsy is 
highly informative, NASH fibrosis staging system may not universally and precisely predict 
outcomes, although the use of quantitative assessment of fibrosis by morphometry may improve 
its predictive performance in NASH. [72]  
Moreover, even when cirrhosis is established, collagen continues to accumulate, yet standard 
pathologic scoring systems are not able to detect this increase, whereas morphometric 
assessment of collagen may be more accurate. [73] While genetic determinants of fibrosis 
progression have been well validated in HCV, a similar fibrosis risk score has not been widely 
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validated in NASH. [74-76] This is probably due to the multifactorial nature of NASH and lack 
of identical contributions from different pathogenic drivers in all patients who present with 
histologic and clinical NASH phenotype. [74-76]  
As a result of the complexity and multifactorial nature for underlying NASH, there is an 
unusually broad effort to focus on many targets, alone or in combination. Among antifibrotic 
therapies, in addition to those previously discussed [FXR agonists, PPAR agonists, and inhibitor 
of apoptosis signal-regulating kinase 1 (ASK1)], are combinations of antagonists which include: 
CCR2/CCR5 chemokine receptors, galectin antagonists, and a siRNA target in stellate cells that 
reduces expression of heat shock protein. [78]. Cenicriviroc (CVC), a CCR2/CCR5 chemokine 
receptor blocker, aims to mediate interactions driving inflammation and fibrosis. In a two year 
Phase 2b multinational, randomized, double-blind placebo-controlled study for the treatment of 
NASH in 289 adults using CVC, year one results have demonstrated improvement in fibrosis 
without worsening of NASH for subjects who received CVC.  The safety profile was also found 
to be encouraging as the only drug-related treatment emergent adverse events with a grade >2 
and having greater than 2% frequency were fatigue (2.8%) and diarrhea (2.1%). (79) 
There are many more compounds undergoing evaluation in animal models to reverse existing 
fibrosis.  Should any one of these prove effective in a clinical trial, it will likely have a catalyzing 
effect on the field. An exciting observation from antiviral trials has been the recognition that cure 
of HCV or suppression of HBV can often reverse cirrhosis, something unimaginable decades 
ago. [78] Uncovering and exploiting mechanisms by which the liver innately degrades scar in 
these diseases could yield new therapeutic approaches that could transform the outlook for 
patients with chronic fibrosing liver disease, including NASH. 
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CONCLUSIONS 
Despite a great deal of advances in understanding the epidemiology of NAFLD and NASH, 
currently, the only available treatment for NAFLD/NASH is weight loss. One of the important 
challenges in the field of NASH is the lack of a reliable and non-invasive endpoint for NASH 
that can accurately serve as a surrogate for the hard outcome of mortality. In this context, there is 
still a great deal of debate about the appropriate endpoints for clinical trials of NASH. Although 
histologic assessment is currently the most widely used modality, it is suboptimal and invasive. 
Nevertheless, resolution of NASH and/or improvement of fibrosis have been the currently 
accepted endpoints. 
In this context, there are emerging therapies for NASH which include non-antifibrotic as well as 
antifibrotic regimens. Most recent clinical trials have focused on NASH and fibrosis as the most 
appropriate candidates for these regimens. Although most clinical trials have focused on 
monotherapy, combination of different drugs targeting different pathogenic pathways in NASH, 
may be most appropriate. There is a great deal of enthusiasm and interest in this area of liver 
disease with potential effective treatment on the horizon. 
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Table 1: Non- Antifibrotic Drugs in Development and their Potential Site of Action 
Drug Name Potential Action Site 
NGM282 Recombinant FGF-19 agonist 
BMS-986036 Pegylated FGF-21 analogue 
JKB-121 (Nalmefene hydrochloride)  TLR-4 antagonist 
Page 30 of 30
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
30 
 
Aramchol  Synthetic fatty acid/bile acid conjugate 
Volixibat  ASBT inhibitor 
MGL-3196- thyroid hormone receptor-β agonist 
GS-0976  ACC inhibitor 
LMB763  FXR agonist 
LJN45 FXR agonist 
Emricasan  oral caspase inhibitor 
Saroglitazar-  PPAR α/ɣ agonist 
IVA337  pan PPAR agonist 
MSDC 0602K mTOR modulating insulin sensitizer 
Semaglutide  GLP-1 analogue 
Liraglutide  GLP-1 analogue 
Combination GS-0976 and GS-9674 ACC inhibitor/ FXR agonist 
IMM-124E- Hyperimmune bovine 
colostrum   
induction of regulatory T cells 
BI-1467335 VAP-1/AOC3 inhibitor 
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